All In Biotech

NDA 202860 · Vero Biotech INC

Genosyl

Nitric Oxide · Inhalation · Vasodilator

Orphan

Last checked: Nov 20, 2026Latest source record: Dec 20, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Dec 20, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

478

75 Phase 3, 30 recruiting

FAERS reports

3,897

2,237 serious, 941 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 11, 2025.

GENOSYL ® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents. GENOSYL ® is a vasodilator indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents ( 1 ).

Mechanism: Nitric oxide relaxes vascular smooth muscle by binding to the heme moiety of cytosolic guanylate cyclase, activating guanylate cyclase and increasing intracellular levels of cyclic guanosine 3',5'-monophosphate, which then leads to vasodilation. When inhaled, nitric oxide selectively dilates the pulmonary vasculature, and because of efficient scavenging by hemoglobin, has minimal effect on the systemic vasculature. GENOSYL appears to increase the partial pressure of arterial oxygen (PaO 2 ) by dilating pulmonary vessels in better ventilated areas of the lung, redistributing pulmonary blood...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 20, 2019 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLabelLetterReview
1 products under this application
  • GENOSYL · NITRIC OXIDE 800PPM · GAS, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nitric Oxide" as an intervention, any sponsor and status, largest first.

All 478 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • no adverse event780
  • device malfunction637
  • underdose476
  • device issue424
  • drug ineffective314
  • off label use237
  • death232
  • product use issue210
  • condition aggravated180
  • oxygen saturation decreased167
  • respiratory failure139
  • pulmonary hypertension137

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20059
200617
200771
200821
200916
201019
201131
20129
201340
201435
201544
201647
201745
201872
201996
2020124
2021430
2022588
2023466
2024687
2025655
2026374

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,105 on PubMed

Sponsor: Vero Biotech INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.